SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broad software sector sell-off, fueled by investor concerns that rapidly advancing AI will disrupt or replace traditional SaaS models. While some analysts and market participants argue that AI will enhance core enterprise software and point to a significant government contract, the community remains polarized between those calling it a "generational buying opportunity" and those fearing further valuation compression.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is buzzing with conversation after its recent financial update, which showcased impressive membership growth and an optimistic 2026 outlook, fueling bullish enthusiasm despite concerns over a quarterly performance miss and ongoing uncertainty surrounding broader healthcare policy.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv (FISV) is actively trending as investors keenly await its earnings report, fueling intense community debate between those who believe the stock is deeply undervalued with a promising turnaround under new leadership, and others bracing for a significant drop mirroring previous disappointments and broader fintech sector headwinds. Significant options activity indicates widespread expectation of a volatile price movement following the announcement.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to its strong Q4 earnings beat and robust subscriber growth, alongside recent premium subscription price increases. The community is widely debating if these positive catalysts, coupled with new AI features and video content, can reverse the stock's recent downtrend and its perceived correlation with Netflix's performance, as many consider it oversold.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is at a pivotal moment as its Q4 earnings report is highly anticipated, with the community actively debating whether the recent significant sell-off presents a buying opportunity. Despite broader software sector concerns and increased competition, many highlight Datadog's critical role in monitoring AI-driven cloud infrastructure and its strong customer relationships, while some analysts have adjusted price targets reflecting mixed expectations for performance amidst a valuation reset.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following strong Q4 earnings, optimistic FY2026 guidance, and reaffirmed targets for profitability by 2027, with the community actively discussing its potential as the 'Amazon of Africa' amidst bullish analyst coverage.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending following its earnings report, which revealed a revenue miss primarily due to weak North American demand, sparking community discussions about its recent rally and overbought conditions despite an earnings per share beat and strong performance in the broader consumer staples sector.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending after securing crucial Medicare coverage for its ultra-sensitive Molecular Residual Disease (MRD) test, marking a significant de-risking milestone for the company. The community is highly optimistic about this pivotal step, anticipating substantial revenue growth and further approvals to solidify Personalis's position in the rapidly evolving cancer diagnostics market.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors digest mixed Phase 2b results for its alopecia areata drug, with community discussion focused on the significance of efficacy data achieved after excluding some patients and the drug's strong safety profile, alongside ongoing speculation about a potential Lilly settlement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

Equity

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 


<ul class="summary-bullets"><li>The company stated that there is no deadline for the strategic alternative finding process.</li><li>The firm also noted that it intends to request an additional meeting with the FDA to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency.</li></ul> Applied Therapeutics, Inc. (APLT) said on Thursday that it is laying off approximately 46% of its workforce as it seeks to conserve cash, while its Board of Directors explores strategic alternatives for the company.The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions to maximise shareholder value, the company<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/20/3191771/0/en/Applied-Therapeutics-Announces-Corporate-Updates.html"> said</a>. There is no deadline for the process, Applied Therapeutics noted, while also adding that the review might not result in a transaction.<h2 class="st-heading-2">Drug Pipeline Updates</h2>The company also said it intends to request an additional meeting with the U.S. Food and Drug Administration to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency. In this disorder, the body can’t properly metabolize sorbitol, leading to its toxic accumulation that damages peripheral nerves and causes progressive symptoms like limb weakness, numbness, and difficulty walking.The company held a meeting with the FDA in the third quarter and is now evaluating the meeting minutes and follow-up correspondence.It is also evaluating the next steps for developing Govorestat for the treatment of Classic Galactosemia, a disorder in which the body cannot break down the sugar galactose. &nbsp;Govorestat is the company’s lead drug candidate for the treatment of CNS rare metabolic diseases or inherited conditions affecting the brain, such as Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, and phosphomannomutase 2 congenital disorder of glycosylation.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/APLT">APLT shares</a> traded marginally in the red at the time of writing. On Stocktwits, retail sentiment stayed within the ‘extremely bullish’ territory over the past 12 months while message volume stayed at ‘extremely high’ levels.APLT shares fell 67% this year and by 97% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Applied Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Mesoblast (MESO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorsmedia.mesoblast.com/static-files/45831458-f1fc-48e1-ae2c-ede16ee03af2">said</a> on Thursday it is awaiting the final minutes from the U.S. Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate Revascor. Nasdaq-listed shares of the company rose over 3% by Thursday morning.The biotechnology company is seeking to file an application for the approval of Revascor for the treatment of patients with ischemic chronic heart failure, characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition is estimated to affect 2% of the adult population of the United States.During the meeting held in the first week of June, there was general alignment on items regarding chemistry, manufacturing &amp; controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the company said.The firm added that it is now awaiting the final minutes from the FDA to determine the timeline for a potential approval filing.The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil is currently approved for the treatment of pediatric patients two months of age and older, and the company is looking to expand the scope of its treatment to adults.On Stocktwits, retail sentiment around Mesoblast rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:634/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_10_45_51_AM_png_80e25b67b7.webp" alt="MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="634" height="63"><figcaption>MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the update from the company and said that it is at its “inflection point.”<stembedurl>https://stocktwits.com/Mani86/message/617651955</stembedurl><a href="https://stocktwits.com/symbol/MESO">MESO stock</a> is down by about 41% this year but up by nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cardinal-health-raises-fy25-earnings-guidance/chlgGvBRb6x">Cardinal Health’s Improved FY25 Earnings Guidance Draws Retail Cheer, Stock Inches Toward Record Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Invesco Exchange-Traded Fund Trust II - Invesco Nasdaq Biotechnology ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

IBBQ
Invesco Nasdaq Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBBQ News

IBBQInvesco Nasdaq Biotechnology ETF